Form D · Biotechnology
Vaxxinity, Inc.
Dallas, TX · CIK 0001851657
Offering snapshot reported Mar 31, 2021 · SEC filing
- Reported sold
- $27M Offering amount: $100M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 17, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 31, 2021 | Initial | $26,960,008 | No comparison | 9 | SEC filing |
| Mar 17, 2021 | Initial | $1,352,949,307 | No comparison | 81 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-394199
Source: Form D, filed Mar 31, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Chui | Director |
| Peter Diamandis | Director |
| Mei Mei Hu | Director, Executive |
| Louis Reese | Director |
| Dakin Sloss | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1717 Main Street Suite 3388
Dallas, TX, 75201
Dallas, TX, 75201